Non-alcoholic Steatohepatitis Treatment Market Size, Share and Global Trend By Drug Class (PPAR agonists, FXR-bile acid axis, Anti-oxidants, GLP-1/DPP-4/SGLT-2 agent, Anti-inflammatory agents, Anti-fibrotic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026

Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation caused due to accumulation of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) demonstrate very few or no symptoms at the initial stages. Some symptoms such as fatigue, weight loss, general weakness and ache in the upper right part of belly are observed at later stages. The exact cause of NASH is unknown, but some of the common causes include obesity, type 2 diabetes, high cholesterol & triglycerides and metabolic syndrome.

Currently, there are no treatments available of non-alcoholic steatohepatitis (NASH). The first line of treatment is weight loss through a combination of a healthy diet and exercise. In February 2019, Intercept Pharmaceuticals, Inc., announced positive topline results from pivotal phase 3 regenerate study of obeticholic acid in patients with liver fibrosis due to NASH.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for non-alcoholic steatohepatitis (NASH) treatment. For instance, Seladelpar, which is being studied by CymaBay Therapeutics, Inc., is currently in phase-2 clinical trials for the study to evaluate seladelpar in subjects with nonalcoholic steatohepatitis (NASH)

At present around 50% of the pipeline candidates for non-alcoholic steatohepatitis (NASH) treatment are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for non-alcoholic steatohepatitis (NASH) treatment. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, and description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for non-alcoholic steatohepatitis (NASH) treatment.

The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for non-alcoholic steatohepatitis (NASH) treatment


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for non-alcoholic steatohepatitis (NASH) treatment


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary